Biogen buys Nightstar; Pacira acquires Myoscience; Horizon Pharma announces pricing; STAT with Slingshot Insights; Epizyme announces Equity Offering

Biogen to buy Nightstar for USD 800 Million

Biogen known for its efforts in treatments of multiple sclerosis and spinal muscular atrophy wound up the deal to buy Nightstar. The deal will let Biogen have access to two experimental gene therapies for blindness-causing diseases helping Biogen’s pipeline.

Pacira acquires Myoscience

Pacira Pharmaceuticals is going to acquire Myoscience, a medical device making company, as announced by the later in its press release for up to USD 220 Million. The deal is good news for patients and physicians who are looking for effective non-opioid treatment.

Horizon Pharma plc announces pricing of public offering of its ordinary shares

Horizon Pharma plc focused on researching and developing innovative medicines, announced the pricing of its underwritten public offering of 12,244,898 of its ordinary shares at a price of USD 24.50 per share making an offering size of up to USD 300 Million. The company will use the proceeds to repay USD 550 Million of outstanding debt.

A new joint venture of STAT with Slingshot Insights

STAT, a national life sciences news organization, has partnered with Slingshot Insights– the first crowd-funded expert network and due diligence community focused on health care, to launch a new service to connect health care investors with subject matter experts and top-tier industry reporters called STAT Expert Advantage.

Epizyme announces Equity Offering

Epizyme (EPZM) announced the pricing of two concurrent underwritten public offerings of (i) 10,000,000 shares of its common stock and (ii) 304,348 shares of its non-voting Series-a Convertible Preferred Stock. Epizyme has granted the underwriters a 30-day option to purchase them. The net proceeds expected to be around USD 150 Million will be used to fund global development and for the commercialization of tazemetostat.